Apellis Pharmaceuticals Inc expected to post a loss of 69 cents a share - Earnings Preview
23/02/2024 15:30
* Apellis Pharmaceuticals Inc APLS.OQ APLS.O is expected
to show a rise in quarterly revenue when it reports results on
February 27 for the period ending December 31 2023
* The Waltham Massachusetts-based company is expected to
report a
533.6% increase in revenue to $143.593 million from $22.66
million a year ago, according to the mean estimate from 16
analysts, based on LSEG data. (Majority is on Total Revenue
basis)
* LSEG's mean analyst estimate for Apellis Pharmaceuticals
Inc is
for a loss of 69 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is $80.00, above its last closing price
of $67.59.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.80 -0.86 -1.17 Missed -36.8
Jun. 30 2023 -1.32 -1.32 -1.02 Beat 22.9
Mar. 31 2023 -1.50 -1.46 -1.56 Missed -6.5
Dec. 31 2022 -1.57 -1.57 -1.50 Beat 4.3
Sep. -1.46 -1.45 -1.75 Missed -20.4
30 2022
Jun. 30 2022 -1.34 -1.36 -1.46 Missed -7
Mar. 31 2022 -1.28 -1.32 -1.42 Missed -7.6
Dec. 31 2021 -1.48 -1.54 -1.61 Missed -4.7
This summary was machine generated February 23 at 15:29 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)